Antibiotice Ia
Research Antibiotice Ia (ATB) on Bullrun: valuation model: 17.9% overvalued, market cap RON 1.44B, P/E 42.9, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATB
- ExchangeRO
- CountryRomania
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyRON
- Valuation signal17.9% overvalued
- Market capRON 1.44B
- P/E42.9
- Dividend yield1.0%
- Financial periodQ4 2025
- RevenueRON 176.92M
- Net incomeRON 9.13M
- Free cash flowRON 24.29M
- Gross margin63.2%
Valuation Snapshot
Bullrun's latest valuation model marks Antibiotice Ia as 17.9% overvalued; latest market cap is RON 1.44B; P/E is 42.9; dividend yield is 1.0%.
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices;
Frequently asked questions
Is Antibiotice Ia overvalued or undervalued?
Bullrun's valuation model currently marks Antibiotice Ia as 17.9% overvalued.
What is Antibiotice Ia's market cap?
Antibiotice Ia's market capitalization is RON 1.44B.
What is Antibiotice Ia's P/E ratio?
Antibiotice Ia's price-to-earnings (P/E) ratio is 42.9.
Does Antibiotice Ia pay a dividend?
Antibiotice Ia has a dividend yield of 1.0%.
What does Antibiotice Ia do?
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class,...